Point72 Asia (Singapore) Pte. Ltd. Beam Therapeutics Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $379 Billion
- Q4 2024
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 7,708 shares of BEAM stock, worth $179,596. This represents 0.05% of its overall portfolio holdings.
Number of Shares
7,708Holding current value
$179,596% of portfolio
0.05%Shares
2 transactions
Others Institutions Holding BEAM
# of Institutions
253Shares Held
78.6MCall Options Held
304KPut Options Held
142K-
Farallon Capital Management LLC San Francisco, CA8.24MShares$192 Million1.09% of portfolio
-
Black Rock Inc. New York, NY7.63MShares$178 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.62MShares$178 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl7.07MShares$165 Million1.53% of portfolio
-
Arch Venture Management, LLC Chicago, IL4.54MShares$106 Million70.85% of portfolio
About Beam Therapeutics Inc.
- Ticker BEAM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,354,600
- Market Cap $1.64B
- Description
- Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...